Abstract
Rosuvastatin calcium (Crestor; AstraZeneca), the seventh drug in the statin class, was approved by the US FDA in August 2003 for the reduction of cholesterol levels in patients with hypercholesterolaemia. Billed as the most potent statin available, can it overcome initial setbacks and make a significant impact in the multi-billion-dollar market for cholesterol-lowering drugs?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tobert, J. A. Lovastatin and beyond: the history of the 1HMG-CoA reductase inhibitors. Nature Rev. Drug Discov. 2, 517–526 (2003).
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo controlled trial. Lancet 360, 7–22 (2002).
Sever, P. S. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149–1158 (2003).
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002).
Watanabe, M. et al. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptonates, a novel series of HMG-CoA reductase inhibitors. Bioorg. Med. Chem. 5, 437–444 (1997).
FDA Drug Approvals List [online] (cited 26 Aug 2003). <http://www.fda.gov/cder/foi/label/2003/21366_crestor_lbl.pdf> (2003).
Jones, P. H. et al. for the STELLAR study group. Statin therapies for elevated lipid levels compared across dose ranges to rosuvastatin: low-density lipoprotein cholesterol and high density lipoprotein cholesterol results. J. Am. Coll. Cardiol. 92, 152–160 (2003).
Earl, J. & Kirkpatrick, P. Ezetimibe. Nature Rev. Drug Discov. 2, 97–98 (2003).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Quirk, J., Thornton, M. & Kirkpatrick, P. Rosuvastatin calcium. Nat Rev Drug Discov 2, 769–770 (2003). https://doi.org/10.1038/nrd1205
Issue Date:
DOI: https://doi.org/10.1038/nrd1205
This article is cited by
-
Evaluating the effect of cinnamon and rosuvastatin, on the formation of foam cells in macrophages co-cultured with platelets
Advances in Traditional Medicine (2022)
-
Synthesis of deuterium-labeled rosuvastatin calcium
Journal of Radioanalytical and Nuclear Chemistry (2020)
